

RECEIVED
CENTRAL FAX CENTER

AUG 29 2006

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)


Total Number of Pages in This Submission

Application Number	10/803,237
Filing Date	3/18/2004
First Named Inventor	Beat Heer, et al.
Art Unit	1616
Examiner Name	Alton Nathaniel Pryor
Attorney Docket Number	A01503

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input checked="" type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Rohm and Haas Company		
Signature			
Printed name	Kenneth Crimaldi		
Date	8/25/06	Reg. No.	40,968

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature



Typed or printed name

Janice Soulus

Date

8-29-06

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED
CENTRAL FAX CENTER

AUG 29 2006

PTO/SB/17 (01-06)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

**FEE TRANSMITTAL
For FY 2006**

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 500.00)

Complete If Known

Application Number	10/803,237
Filing Date	3/18/2004
First Named Inventor	Beat Heer, et al.
Examiner Name	Alton Nathaniel Pryor
Art Unit	1616
Attorney Docket No.	A01503

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order None Other (please identify): _____

Deposit Account Deposit Account Number: 18-1850 Deposit Account Name: Rohm and Haas Company

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee

Charge any additional fee(s) or underpayments of fee(s) Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION (All the fees below are due upon filing or may be subject to a surcharge.)

1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fee Paid (\$)
	Fee (\$)	Small Entity	Fee (\$)	Small Entity	Fee (\$)	Small Entity	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description

Fee Description	Fee (\$)	Small Entity
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims	Fee (\$)	Fee Paid (\$)
- 20 or HP =	x	=				

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims	Fee (\$)	Fee Paid (\$)
- 3 or HP =	x	=				

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(c)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
- 100 =	/ 50 =	(round up to a whole number) x	=	

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): Appeal Brief

Fee Paid (\$)

500.00

SUBMITTED BY

Signature	Kenneth Crimaldi	Registration No. (Attorney/Agent) 40,968	Telephone 215-592-3000
Name (Print/Type)	Kenneth Crimaldi	Date 8/25/06	

This collection of information is required by 37 CFR 1.138. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED
CENTRAL FAX CENTER
AUG 29 2006

GROUP ART UNIT: 1616
APPEAL NO. _____

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE BOARD OF APPEALS AND INTERFERENCES**

APPEAL BRIEF

In re the Application of Beat Heer et al.

Filed: March 18, 2004

Serial No. 10/803,237

For: MICROBICIDAL COMPOSITION

Kenneth Crimaldi
Attorney for Appellants

Alton Nathaniel Pryor
Examiner

Enclosed:
Transmittal Form

08/30/2006 EAREGAY1 00000018 181850 10803237
01 FC:1402 500.00 DA

RECEIVED
CENTRAL FAX CENTER

10/803,237
August 23, 2006

A01503

AUG 29 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Beat Heer et al. : :

Application No.: 10/803,237 : Group No.: 1616

Filed: March 18, 2004 : Examiner: Alton Nathaniel Pryor

For: MICROBICIDAL COMPOSITION

MAIL STOP APPEAL BRIEF - PATENTS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

APPEAL BRIEF

This is an appeal from the rejection dated June 5, 2006 finally rejecting claims 1, 6-8 and 10-12. The rejected claims are set out in Appendix J. Appellants filed a Notice of Appeal pursuant to 37 C.F.R. § 1.191 on August 17, 2006.

(B) Table of Contents

(C) Real party in interest	4
(D) Related appeals and interferences	5
(E) Status of claims	6
(F) Status of amendments	7
(G) Summary of claimed subject matter	8
(H) Grounds of rejection to be reviewed on appeal	9
(I) Argument	10-13
(J) Claims appendix	14-15
(K) Evidence appendix	16
(L) Related proceedings appendix	17

10/803,237
August 23, 2006

A01503

(C) Real Party In Interest

The owner of the present application and the invention contained therein is
ROHM AND HAAS COMPANY.

10/803,237
August 23, 2006

A01503

(D) Related Appeals, Interferences or Judicial Proceedings

No appeals, interferences or judicial proceedings are known to Appellants, the Appellants' legal representative, or the assignee which will directly affect or be directly affected by or have a bearing on the Board's decision in the pending appeal.

10/803,237
August 23, 2006

A01503

(E) Status Of Claims

The status of the claims is as follows:

Claims pending: 1 and 3-12

Allowed claims: 3-5 and 9

Claims objected to: none

Claims canceled: 2

Claims rejected: 1, 6-8 and 10-12

Claims on appeal: 1, 6-8 and 10-12

Claims withdrawn from consideration by the Examiner: none.

10/803,237
August 23, 2006

A01503

(F) Status Of Amendments

Appellants have not filed an amendment after final rejection in the present application.

(G) Summary of Claimed Subject Matter

Claim 1: The present invention provides a microbicidal composition comprising:

(a) at least one non-halogenated 2-alkyl-4-isothiazolin-3-one selected from substituted and unsubstituted 2-(C₁-C₄)alkyl-4-isothiazolin-3-ones [page 1, lines 19-20]; and

(b) at least one of 2,2'-dithiobis(N-methylbenzamide) and 2-methylbenzisothiazolone [page 1, lines 21-22];

wherein a weight ratio of said at least one non-halogenated 2-alkyl-4-isothiazolin-3-one to said at least one of 2,2'-dithiobis(N-methylbenzamide) and 2-methylbenzisothiazolone is from 750:1 [page 3, lines 26-28] to 1:1 [page 10, Table 1, 5th row].

10/803,237
August 23, 2006

A01503

(H) Grounds of Rejection to be Reviewed on Appeal

Claims 1, 6-8 and 10-12 stand rejected under 35 USC § 102(b) as being anticipated by Yamaguchi (JP 2001302418).

(I) Argument

Regarding whether or not claims 1, 6-8 and 10-12 are unpatentable over Yamaguchi:

(a) Yamaguchi Fails to Disclose at Least One Limitation of the Present Claims

All claim limitations must be taught or suggested in the prior art. *In re Royka*, 490 F.2d 981 (C.C.P.A. 1974). At least two key limitations of independent claim 1 are not taught or suggested in any of the cited references, namely: (i) the combination of “at least one non-halogenated 2-alkyl-4-isothiazolin-3-one selected from substituted and unsubstituted 2 (C₁-C₄)alkyl-4-isothiazolin-3-ones” with “at least one of 2,2'-dithiobis(N-methylbenzamide) and 2-methylbenzisothiazolone;” and (ii) “a weight ratio of said at least one non-halogenated 2-alkyl-4-isothiazolin-3-one to said at least one of 2,2'-dithiobis(N-methylbenzamide) and 2-methylbenzisothiazolone [is] from 750:1 to 1:1.”

The final Office Action asserts that “Yamaguchi teaches a combination comprising 99 to 1 parts MIT and 1 to 99 parts MBI.” In fact, the disclosure of Yamaguchi is not specific, disclosing only a microbicide containing “1 to 99 parts by weight of a benzisothiazolone derivative of general formula I and 99 to 1 parts by weight of an isothiazolone derivative of general formula II.” (para. [0009], emphasis added). Therefore, Yamaguchi does not teach the claimed combination of biocides. Moreover, Yamaguchi does not disclose the claimed range of biocide ratios from 750:1 to 1:1. Accordingly, Yamaguchi does not teach key limitations of claim 1.

(b) Yamaguchi Fails to Disclose the Claimed Invention with Sufficient Specificity

1. The Claimed Biocide Combination is not Disclosed

The disclosure of Yamaguchi, as discussed in part (a) above, relates only to a genus containing many compounds, and not the species recited in independent claim 1. “It is well established that the disclosure of a genus in the prior art is not necessarily a disclosure of every species that is a member of that genus.” *Atofina v. Great Lakes*

Chem. Corp., 441 F.3d 991, 999 (Fed. Cir. 2006). Although a small genus can be a disclosure of species, *see In re Petering*, 301 F.2d 676 (C.C.P.A. 1962), the disclosure must have “sufficient specificity to anticipate” the claim. *Atofina* at 1000. Yamaguchi discloses, in general formulas I and II, a great many compounds (para. [0011]). For example, in formula II, R1 and R2 each may be hydrogen or C₁-C₄ alkyl (8 choices¹), to give 9x9=81 possibilities. R3 may be hydrogen, C₁-C₆ alkyl (33 choices²) or C₁-C₄ alkoxy (8 choices, as for C₁-C₄ alkyl), to give a total of 42x81=3,402 possibilities for Formula II. Formula I has somewhat fewer, but with >>34 choices for R (H or C₁-C₈ alkyl), although they are multiplied by only 2 choices for X, there still are hundreds of thousands of total possibilities when the possibilities for Formula I are subsequently multiplied by the 3,402 for formula II.

Even if, *assuming arguendo*, one were to limit Yamaguchi’s general disclosure to the compounds listed in paragraphs [0013] and [0014] (although these are listed only as “examples” and not as “preferred” compounds), there still would be eight compounds mentioned within formula I and six for formula II, giving 48 possible biocide combinations. When the C.C.P.A. found, in *Petering*, that a genus could anticipate a species, there were only 20 compounds in the genus. *Petering* at 681. In the present case, a larger number of combinations is possible in the disclosure of Yamaguchi, none of which has been identified specifically. Moreover, as pointed out previously, the more limited disclosure of paragraphs [0013] and [0014] is not “preferred,” and would appear to one skilled in the art to be merely a listing of common biocides, rather than a teaching of effective combinations. Therefore, Yamaguchi does not disclose the species within Appellants’ claimed combination of biocides, and cannot anticipate the present invention.

2. The Claimed Range of Biocide Ratios is not Disclosed

Synergy has been demonstrated in the present invention over the claimed range from 750:1 to 1:1, whereas the reference discloses a range of 99:1 to 1:99. The

¹ The possibilities are: methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl and t-butyl.

² The possibilities are: methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, n-pentyl, 2-pentyl, 3-pentyl, isopentyl, 2-methylbutyl, neopentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, n-hexyl, 2-hexyl, 3-hexyl, isohexyl, 3-methylpentyl, 2-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-

reference thus teaches a broad range, not supported by data, for a large number of biocide combinations, while the present invention demonstrates synergy for an overlapping, but quite distinct range. "If the claims are directed to a narrow range, the reference teaches a broad range, and there is evidence of unexpected results within the claimed narrow range, depending on the other facts of the case, it may be reasonable to conclude that the narrow range is not disclosed with 'sufficient specificity' to constitute an anticipation of the claims." M.P.E.P. § 2131.03(II); *see also Atofina v. Great Lakes Chem. Corp.*, 441 F.3d 991 (Fed. Cir. 2006). In *Atofina*, the prior art range of 100 to 500°C completely encompassed the claimed range of 330 to 450°C, yet the Federal Circuit held that "[g]iven the considerable difference between the claimed range and the range in the prior art, no reasonable fact finder could conclude that the prior art describes the claimed range with sufficient specificity to anticipate this limitation of the claim." *Atofina* at 999. Moreover, the court also held that a prior art range of 0.001 to 1.0% did not anticipate a range of 0.1 to 5.0%, "although there is a slight overlap." *Id.* at 1000. In this case, Yamaguchi's range overlaps with Appellants' claimed range, and moreover, Yamaguchi discloses only a totally speculative range of biocide ratios. Appellants have shown that the claimed biocide combinations are synergistic only over part of the range disclosed in Yamaguchi. Beyond a ratio of 1:20, Appellants observed no synergy (see page 10), although Yamaguchi's range goes up to 1:99. Moreover, Appellants have observed synergy beyond 99:1, the other end of Yamaguchi's range. Yamaguchi does not disclose Appellants' observed and claimed range of synergistic ratios, but in fact discloses non-synergistic ratios and fails to disclose some synergistic ratios. Therefore, Appellants respectfully submit that the disclosure of the reference lacks "sufficient specificity" to support the anticipation rejection, according to the standards set forth in the M.P.E.P. and *Atofina*.

3. Claims 7 and 10

These dependent claims narrow the isothiazolone biocide from "substituted and unsubstituted 2-(C₁-C₄)alkyl-4-isothiazolin-3-ones" to a single biocide, 2-methyl-4-

dimethylbutyl, 2,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl and 1,2,2-trimethylpropyl.

10/803,237
August 23, 2006

A01503

isothiazolone-3-one. Since claims 7 and 10 recite a more limited combination of biocides than claim 1, Yamaguchi is still further from disclosing the claimed invention with "sufficient specificity to anticipate" these claims. *Atofina* at 1000.

CONCLUSION

Based on the foregoing, Appellants respectfully submit that the pending claims are currently in condition for allowance. Appellants respectfully request the Board to pass the pending claims to allowance.

Enclosed herewith, Appellants have filed a Certificate of Mailing to establish the timely filing of this Appeal Brief.

The Commissioner is hereby authorized to charge any additional fee which may be required, or to credit any overpayments to Deposit Account 18-1850.

Respectfully submitted,



Kenneth Crimaldi
Attorney for Appellants
Registration No. 40,968

ROHM AND HAAS COMPANY
100 Independence Mall West
Philadelphia, PA 19106-2399
August 23, 2006

(J) Claims Appendix

1. A microbicidal composition comprising:
 - (a) at least one non-halogenated 2-alkyl-4-isothiazolin-3-one selected from substituted and unsubstituted 2-(C₁-C₄)alkyl-4-isothiazolin-3-ones; and
 - (b) at least one of 2,2'-dithiobis(N-methylbenzamide) and 2-methylbenzisothiazolone;
wherein a weight ratio of said at least one non-halogenated 2-alkyl-4-isothiazolin-3-one to said at least one of 2,2'-dithiobis(N-methylbenzamide) and 2-methylbenzisothiazolone is from 750:1 to 1:1.
6. The composition of claim 1 in which said at least one of 2,2'-dithiobis(N-methylbenzamide) and 2-methylbenzisothiazolone is 2-methylbenzisothiazolone and said weight ratio is from 750:1 to 2.5:1.
7. The composition of claim 6 in which said at least one non-halogenated 2-alkyl-4-isothiazolin-3-one is 2-methyl-4-isothiazolin-3-one.
8. The composition of claim 7 in which said weight ratio is from 125:1 to 2.5:1.
10. The composition of claim 1 in which said at least one non-halogenated 2-alkyl-4-isothiazolin-3-one is 2-methyl-4-isothiazolin-3-one.
11. A household product, cosmetic, toiletry, shampoo, soap or detergent comprising the microbicidal composition of claim 10.

12. The household product, cosmetic, toiletry, shampoo, soap or detergent of claim 11 in which said at least one of 2,2'-dithiobis(N-methylbenzamide) and 2-methylbenzisothiazolone is 2-methylbenzisothiazolone and said weight ratio is from 750:1 to 2.5:1.

10/803,237
August 23, 2006

A01503

(K) Evidence Appendix

No evidence was submitted during prosecution.

10/803,237
August 23, 2006

A01503

(L) Related Proceedings Appendix

There are no related proceedings.